Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy

Lancet Oncol. 2022 Aug;23(8):962-963. doi: 10.1016/S1470-2045(22)00383-7. Epub 2022 Jul 4.

Authors

Fanpu Ji¹, Mindie H Nguyen²

Affiliations

¹ Department of Infectious Diseases, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
² Division of Gastroenterology and Hepatology, and Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, CA 94304, USA. Electronic address: mindiehn@stanford.edu.

PMID: 35798015
DOI: 10.1016/S1470-2045(22)00383-7

No abstract available

Publication types

Comment

MeSH terms

Anilides / adverse effects
Antibodies, Monoclonal, Humanized*
Antiviral Agents / therapeutic use
Carcinoma, Hepatocellular* / drug therapy
Carcinoma, Hepatocellular* / pathology
Humans
Liver Neoplasms* / drug therapy
Liver Neoplasms* / pathology
Pyridines

Substances

Anilides
Antibodies, Monoclonal, Humanized
Antiviral Agents
Pyridines
cabozantinib
atezolizumab